Our Science

Since 2008, Acasti Pharma’s scientists have focused on the research and development of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of cardiometabolic diseases.

Acasti’s lead drug candidate, CaPre, has completed two Phase 1 bioavailability and pharmacokinetic trials in healthy volunteers, and two Phase 2 clinical trials in patients with hypertriglyceridemia. CaPre is a krill oil-derived mixture of polyunsaturated fatty acids (PUFAs), primarily composed of omega-3 fatty acids: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are present as a combination of phospholipid esters and free fatty acids.